Oncotarget

Research Papers:

Folic acid conjugation improves the bioavailability and chemosensitizing efficacy of curcumin-encapsulated PLGA-PEG nanoparticles towards paclitaxel chemotherapy

Arun Kumar T. Thulasidasan, Archana P. Retnakumari, Mohan Shankar, Vinod Vijayakurup, Shabna Anwar, Sanu Thankachan, Kavya S. Pillai, Jisha J. Pillai, C. Devika Nandan, Vijai V. Alex, Teena Jacob Chirayil, Sankar Sundaram, Gopalakrishnapillai Sankaramangalam Vinod Kumar and Ruby John Anto _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:107374-107389. https://doi.org/10.18632/oncotarget.22376

Metrics: PDF 1184 views  |   HTML 1914 views  |   ?  


Abstract

Arun Kumar T. Thulasidasan1,3,*, Archana P. Retnakumari1,*, Mohan Shankar1,4, Vinod Vijayakurup1, Shabna Anwar1,3, Sanu Thankachan1, Kavya S. Pillai1, Jisha J. Pillai2, C. Devika Nandan2, Vijai V. Alex1, Teena Jacob Chirayil2,3, Sankar Sundaram5, Gopalakrishnapillai Sankaramangalam Vinod Kumar2 and Ruby John Anto1

1Division of Cancer Research, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India

2Division of Chemical Biology-Nano Drug Delivery Systems, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India

3Research Scholar, University of Kerala, Thiruvananthapuram, Kerala, India

4Research Scholar, Manipal University, Manipal, Karnataka, India

5Department of Pathology, Government Medical College, Kottayam, Kerala, India

*These authors contributed equally to this work

Correspondence to:

Ruby John Anto, email: rjanto@rgcb.res.in

Keywords: curcumin; folic acid conjugation; PLGA nanoparticles; bioavailability; chemosensitization

Received: May 31, 2017     Accepted: October 25, 2017     Published: November 10, 2017

ABSTRACT

Nanoencapsulation has emerged as a novel strategy to enhance the pharmacokinetic and therapeutic potential of conventional drugs. Recent studies from our lab have established the efficacy of curcumin in sensitizing cervical cancer cells and breast cancer cells towards paclitaxel and 5-FU chemotherapy respectively. Factors that hinder the clinical use of curcumin as a sensitizer or therapeutic agent include its poor bioavailability and retention time. Earlier reports of improvement in bioavailability and retention of drugs upon nanoencapsulation have motivated us in developing various nanoformulations of curcumin, which were found to exhibit significant enhancement in bioavailability and retention time as assessed by our previous in vitro studies. Among the various formulations tested, curcumin-entrapped in PLGA-PEG nanoparticles conjugated to folic acid (PPF-curcumin) displayed maximum cell death. In the present study, we have demonstrated the efficacy of this formulation in augmenting the bioavailability and retention time of curcumin, in vivo, in Swiss albino mice. Further, the acute and chronic toxicity studies proved that the formulation is pharmacologically safe. We have also evaluated its potential in chemosensitizing cervical cancer cells to paclitaxel and have verified the results using cervical cancer xenograft model in NOD-SCID mice. Folic acid conjugation significantly enhanced the efficacy of curcumin in down-regulating various survival signals induced by paclitaxel in cervical cancer cells and have considerably improved its potential in inhibiting the tumor growth of cervical cancer xenografts. The non-toxic nature coupled with improved chemosensitization potential makes PPF-curcumin a promising candidate formulation for clinical trials.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22376